Comparison of Tumor Size and Gene Expression at Presentation in Uveal Melanoma Patients before and during the COVID-19 Pandemic.
Ocul Oncol Pathol
; 8(3): 156-160, 2022 Nov.
Article
in English
| MEDLINE | ID: covidwho-2138274
ABSTRACT
Introduction:
The aim of this study was to compare the clinical and gene expression variables of uveal melanoma patients presenting before and after the start of the COVID-19 pandemic as surrogate markers in order to assess the pandemic's potential impact on care.Methods:
We conducted a retrospective chart review of uveal melanoma patients at Retina Consultants of Texas and assessed tumor size, staging, and gene expression data during two time periods May 2019 to February 2020 (Group 1 Before the COVID-19 pandemic declaration by the WHO in March 2020) and May 2020 to March 2021 (Group 2 After the start of the COVID-19 pandemic).Results:
A total of 80 patients with uveal melanoma were studied (Group 1 40 [50%] and Group 2 40 [50%]). There was no statistically significant difference in the tumor thickness (p = 0.768), largest base dimension (p = 0.758), Collaborative Ocular Melanoma Study size class (p = 0.762), and American Joint Committee on Cancer stages (p = 0.872) between the two groups. Additionally, there was no difference in the tumors' gene expression data including gene expression profile class (p = 0.587) and PRAME expressivity (p = 0.861) between the two groups. Discussion/Conclusion:
The COVID-19 pandemic had no effect on the presentation of uveal melanoma patients across all tumor characteristics including size, staging, and gene expression data, suggesting there was not a significant diagnostic delay in care for uveal melanoma patients at our center due to the pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Ocul Oncol Pathol
Year:
2022
Document Type:
Article
Affiliation country:
000524918
Similar
MEDLINE
...
LILACS
LIS